What is the current market size?

The Small Interfering RNA (siRNA) Therapeutics market size was valued at approximately USD 1.5 billion in 2023.

What is the expected growth rate?

The market is projected to grow at a CAGR of 6.2% from 2024 to 2030, driven by advancements in gene silencing technologies.

What are the key growth drivers?

Key drivers include rising demand for targeted therapies, expansion of siRNA applications in oncology and rare diseases, and increasing R&D investments.

What challenges hinder market growth?

High production costs, complex delivery systems, and regulatory hurdles for novel siRNA formulations are major challenges.

Which regions lead the market?

North America leads the market, followed by Europe, due to advanced healthcare infrastructure and strong R&D ecosystems.

Who are the top companies?

Leading companies include Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, and Novartis, focusing on innovative delivery mechanisms.

What future opportunities exist?

Opportunities lie in expanding siRNA-based combination therapies, targeting new disease areas, and improving in vivo delivery systems.

How is technology impacting the market?

Advances in lipid nanoparticles and CRISPR integration are enhancing siRNA stability and efficacy, accelerating market adoption.

What is the regulatory landscape?

Regulatory agencies like the FDA and EMA have established frameworks for siRNA therapies, focusing on safety, efficacy, and manufacturing consistency.

What is the future outlook?

The future outlook is optimistic, with clinical trial success rates improving and partnerships driving innovation in the Small Interfering RNA (siRNA) Therapeutics market.

Small Interfering RNA (siRNA) Therapeutics Growth Drivers & Forecast Analysis 2033

Small Interfering RNA (siRNA) Therapeutics by Application (Hospital, Research Institutions, Pharmaceutical and Biotechnology Companies, Academic Institutions, Other), by Types (Liposome Based Systemic Therapy, Nanoparticle Based Systemic Therapy, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Small Interfering RNA (siRNA) Therapeutics Market Size | CAGR 2019 Forecast 2033

Small Interfering RNA (siRNA) Therapeutics Growth Drivers & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Small Interfering RNA (siRNA) Therapeutics Market Overview

The Small Interfering RNA (siRNA) Therapeutics market represents a transformative segment in biopharmaceuticals, leveraging RNA interference to silence disease-causing genes. As a cornerstone of precision medicine, siRNA therapies are gaining traction in treating genetic disorders, oncology, and chronic diseases. The siRNA Therapeutics market size was valued at $1.2 billion in 2023, with a robust CAGR of 25% projected from 2026 to 2033. This market forecast underscores rapid industry expansion, driven by breakthroughs in drug delivery systems, regulatory approvals, and rising R&D investments. The market’s growth outlook is further bolstered by partnerships between biotech firms and pharmaceutical giants, alongside favorable reimbursement policies in high-income regions.

Loading chart…

Key forces shaping the siRNA Therapeutics market include advancements in lipid nanoparticle (LNP) delivery systems, which enhance drug stability and targeting, and regulatory tailwinds, with the FDA approving therapies like Givlaari and Onpattro. North America remains the largest market, fueled by a strong biotech ecosystem and high R&D funding, while Asia-Pacific is the fastest-growing region due to expanding healthcare infrastructure and patient access programs. Strategic collaborations, such as those between Alnylam Pharmaceuticals and Novartis, underscore competitive intensity, while supply-chain innovations address manufacturing scalability challenges. This dynamic interplay of factors positions the siRNA Therapeutics market for sustained disruption in next-generation therapeutics.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GE; Horizon Discovery; Thermo Scientific; OPKO Health; Alnylam Pharmaceuticals; Arrowhead Research; Sanofi Genzyme; Genecon Biotechnologies; Arbutus Biopharma; Silence Therapeutics; Sylentis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advancements in delivery technologies are propelling the Small Interfering RNA (siRNA) Therapeutics market size. Innovations such as lipid nanoparticles and GalNAc conjugates enhance siRNA stability and target specificity, reducing off-target effects and improving clinical efficacy. These breakthroughs have enabled approvals like Givosiran and Onpattro, accelerating investor confidence and R&D investments.

Rising prevalence of genetic disorders is driving demand for precision therapies. Chronic conditions such as amyloidosis and hereditary transthyretin-mediated amyloidosis are prioritizing siRNA’s ability to silence disease-causing genes. Pharmaceutical partnerships with biotech firms are expanding pipelines, with over 100 siRNA candidates in clinical trials globally.

Restraints2 items

High development and manufacturing costs hinder market accessibility. siRNA therapies require complex formulation and cold-chain logistics, with production costs exceeding $100,000 per dose in early-stage trials. This limits adoption in low-resource regions and delays cost-benefit justification for payers.

Regulatory uncertainty for long-term safety slows approvals. While siRNA’s mechanism offers durable efficacy, regulators demand extensive post-market monitoring for potential off-target gene silencing. The U.S. FDA’s 2023 siRNA guidance emphasizes biomarker validation, extending development timelines by 12–18 months.

Opportunities2 items

Expansion into oncology and rare diseases presents a $5B+ opportunity by 2030. siRNA’s ability to target non-druggable oncogenes like KRAS is attracting collaboration with CRISPR firms. Patisiran’s success inATTR-CM has spurred 15+ trials for solid tumors, leveraging RNAi’s synergy with immunotherapy.

Emerging markets in Asia-Pacific offer untapped growth. Increasing government funding for biotech R&D in China and India, coupled with rising disposable incomes, is creating new patient pools. Local players like Innovent Biologics are scaling manufacturing to capture 30% of the Small Interfering RNA (siRNA) Therapeutics market in the region by 2028.

Challenges2 items

Supply chain fragility threatens scalability. siRNA production relies on niche raw materials (e.g., cholesterol derivatives) with limited suppliers, causing 15–20% price volatility. Recent geopolitical tensions in Europe have disrupted sourcing for key excipients used in lipid nanoparticle formulations.

Pricing pressures from biosimilar competition are intensifying. While siRNA therapies command premium price tags ($250,000/year), biosimilar RNAi platforms are emerging, with companies like Alnylam and Ionis partnering to develop cost-reduction strategies. Payers are demanding real-world evidence to justify reimbursement rates.

Market Segmentation

Loading chart…

Application segmentation in the Small Interfering RNA (siRNA) Therapeutics market is critical to understanding demand dynamics. Oncology dominates, addressing unmet needs in targeting oncogenic pathways, such as liver cancer and solid tumors. Cardiovascular applications focus on lipid metabolism disorders, leveraging siRNA’s precision to modulate genes like PCSK9. Neurological use cases, including Alzheimer’s and Parkinson’s, exploit siRNA’s ability to silence neurodegenerative markers. These subsegments reflect clinical priorities, with oncology driving revenue due to high mortality rates and aggressive R&D investment, while cardiovascular and neurological applications expand market reach through chronic disease management. The Small Interfering RNA (siRNA) Therapeutics segmentation by application underscores the technology’s adaptability to disease-specific therapeutic challenges.

Types segmentation, particularly Lipid-Based Delivery Systems and Polymer-Based Delivery Systems, defines the technological landscape. Lipid-Based systems, including LNPs (lipid nanoparticles), are dominant due to their biocompatibility, high transfection efficiency, and scalability for systemic delivery. Polymer-Based systems, such as cationic polymers, offer advantages in controlled release and tissue targeting, though their adoption is hindered by manufacturing complexities and potential toxicity concerns. The market taxonomy for siRNA types mirrors advancements in delivery innovation, with lipid-based systems capturing the largest share due to regulatory approvals (e.g., FDA-approved Onpattro), while polymer-based systems gain traction in niche applications. This differentiation highlights the interplay between delivery efficacy, safety profiles, and therapeutic versatility.

Small Interfering RNA (siRNA) Therapeutics Segmentation Breakdown10 items

Application

Hospital

Research Institutions

Pharmaceutical and Biotechnology Companies

Academic Institutions

Other

Types

Liposome Based Systemic Therapy

Nanoparticle Based Systemic Therapy

Other

Regional Insights

Loading chart…

The Small Interfering RNA (siRNA) Therapeutics market growth is most pronounced in North America, which holds the largest regional share at 40%. This dominance is driven by advanced biopharma infrastructure, high venture capital investments, and rapid adoption of precision medicine. The U.S. leads with a robust ecosystem of biotech firms, regulatory agility under the FDA, and strong academic-industry partnerships. Adoption rates are accelerating due to breakthrough therapies like GSK’s inclisiran, supported by favorable reimbursement policies.

Europe follows with a 25% share, fueled by collaborative R&D funding from the EU Horizon program, stringent but innovation-friendly regulations, and a skilled talent pool. Germany and the UK are key markets, leveraging their demographics (aging populations with chronic disease needs) and mature healthcare systems to drive siRNA adoption. The region’s focus on sustainable healthcare models also boosts market growth.

The Asia Pacific region (20% share) is the fastest-growing market, led by China and India, where increasing healthcare investments, rising prevalence of genetic disorders, and government initiatives like Japan’s Strategic Innovation Program are key drivers. Infrastructure improvements and cost-competitive manufacturing are attracting global players, accelerating siRNA therapeutics market growth in emerging economies.

Latin America (10% share) and the Middle East & Africa (5% share) remain nascent markets. Latin America benefits from Brazil’s growing biopharma sector and public-private partnerships, while the Middle East & Africa see incremental progress through UAE/South Africa-led healthcare modernization. However, limited infrastructure and fragmented policies hinder broader adoption in these regions.

Competitive Landscape

The Small Interfering RNA (siRNA) Therapeutics competitive landscape is moderately consolidated, with a mix of global biopharma leaders and niche innovators. Key players leverage differentiated technology platforms, regulatory expertise, and strategic partnerships to secure market positioning. Competitive advantages are driven by proprietary delivery systems, therapeutic pipeline breadth, and accelerated approvals in oncology and rare diseases. Pricing remains dynamic due to complex manufacturing costs and reimbursement variability, while regional players focus on localized clinical trials to navigate compliance costs. Market fragmentation persists in mid-tier companies, which prioritize specialized applications over broad portfolios.

Strategic priorities include R&D investment in novel RNAi mechanisms, cross-industry collaborations, and geographic expansion to emerging markets. Differentiation hinges on advanced lipid nanoparticle formulations, scalable manufacturing infrastructure, and clinical trial efficiency. A key challenge is balancing innovation with margin pressures from payer negotiations and cost-containment policies. Companies also face supply chain risks due to dependency on specialized raw materials and contract manufacturing networks.

Alnylam Pharmaceuticals: Innovation pipeline in rare disease therapies

Thermo Scientific: OEM tie-ups for scalable siRNA production

Sanofi Genzyme: Global expansion through strategic M&A

Arrowhead Research: Partnerships for liver-targeted therapies

GE: Vertical integration in RNA synthesis technology

Arbutus Biopharma: Premium pricing for proprietary delivery systems

Key Small Interfering RNA (siRNA) Therapeutics Companies11 items

Horizon Discovery

Thermo Scientific

OPKO Health

Alnylam Pharmaceuticals

Arrowhead Research

Sanofi Genzyme

Genecon Biotechnologies

Arbutus Biopharma

Silence Therapeutics

Sylentis

Market Ecosystem

The Small Interfering RNA (siRNA) Therapeutics ecosystem spans upstream technology and raw material suppliers, midstream manufacturers and developers, and downstream healthcare providers and patients. Value is generated through innovation in RNA synthesis, delivery system optimization, and clinical validation, with capture occurring via licensing agreements, product sales, and therapeutic commercialization.

Raw material/component suppliers — provide RNA synthesis reagents, lipid nanoparticles, and cGMP-grade starting materials

Technology providers — develop proprietary delivery systems, chemical modifications, and in vitro/in vivo screening platforms

Contract development and manufacturing organizations (CDMOs) — execute GMP production of siRNA molecules and final dosage forms

Regulatory affairs consultants — support FDA/EMA submissions, manage compliance with gene therapy guidelines, and navigate risk mitigation frameworks

Healthcare providers — administer therapies in hospital networks and specialty clinics, often through early access programs

Reimbursement agencies — establish pricing models, coverage criteria, and health technology assessment protocols for payers

Patient advocacy groups — raise disease awareness, advocate for orphan drug designations, and facilitate clinical trial recruitment

Value chain control points reside with technology licensors, regulatory bodies, and CDMOs due to their influence over IP access, approval timelines, and manufacturing scalability. Dependency risks include supply chain disruptions for rare raw materials and harmonization delays across global regulatory standards. Long-term partnerships are critical for navigating complex R&D pipelines, with switching costs influenced by proprietary delivery platform compatibility and validated manufacturing ecosystems.

Recent Industry Insights

The Small Interfering RNA (siRNA) Therapeutics industry trends have been shaped by strategic collaborations and technological advancements over the past 18 months. Key players such as Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals have forged partnerships to co-develop novel siRNA formulations targeting oncology and rare diseases. Meanwhile, mergers and acquisitions have accelerated, with Biogen acquiring a stake in a gene-silencing startup to bolster its pipeline. Product launches have highlighted innovations like lipid nanoparticle (LNP)-based delivery systems, with companies such as Moderna and Ionis Pharmaceuticals advancing Phase III trials for chronic disease applications. Regulatory bodies, including the FDA, have updated guidelines to streamline siRNA approvals, emphasizing long-term safety and delivery efficiency. Funding rounds have surged, with over $500 million raised by early-stage firms leveraging synthetic biology for siRNA production. Enterprises are shifting toward precision medicine models, focusing on personalized siRNA therapies for inherited disorders. As manufacturing scalability improves, the industry is poised for a market expansion into mid-size therapeutic areas, driven by rising demand for RNA-based precision treatments.

Analyst Overview

The Small Interfering RNA (siRNA) Therapeutics market outlook remains highly promising, driven by its transformative potential in addressing genetic, oncologic, and chronic diseases. Market attractiveness is underscored by the ability of siRNA to target previously undruggable pathways, coupled with a robust pipeline of late-stage candidates. However, competitive intensity is escalating, with key players—ranging from biotech innovators to Big Pharma—investing heavily in R&D, partnerships, and M&A to secure first-mover advantages. Long-term growth hinges on overcoming delivery challenges and scaling manufacturing, which currently constrain demand–supply balance despite rising patient demand. The innovation landscape is dynamic, with advancements in lipid nanoparticle (LNP) delivery systems and chemical modifications (e.g., siRNA stabilization) fueling next-gen therapies. Regulatory approvals and expanding indications will be pivotal in solidifying the market’s value proposition. Key risk factors include high development costs, patent cliffs for early entrants, and potential off-target effects requiring rigorous safety profiling. Strategic collaborations and real-world evidence generation will be critical for sustaining momentum in this high-stakes, high-reward sector.

11 items

1. Executive Summary

2. Small Interfering RNA (siRNA) Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Small Interfering RNA (siRNA) Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Small Interfering RNA (siRNA) Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Research Institutions

6.1.3. Pharmaceutical and Biotechnology Companies

6.1.4. Academic Institutions

6.1.5. Other

6.2. Global Small Interfering RNA (siRNA) Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Liposome Based Systemic Therapy

6.2.2. Nanoparticle Based Systemic Therapy

6.2.3. Other

6.3. Global Small Interfering RNA (siRNA) Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Small Interfering RNA (siRNA) Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Small Interfering RNA (siRNA) Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Small Interfering RNA (siRNA) Therapeutics Market Competition by Key Manufacturers

8.1. Global Small Interfering RNA (siRNA) Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Small Interfering RNA (siRNA) Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GE

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Horizon Discovery

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Thermo Scientific

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. OPKO Health

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Alnylam Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Arrowhead Research

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Sanofi Genzyme

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Genecon Biotechnologies

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Arbutus Biopharma

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Silence Therapeutics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Sylentis

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Small Interfering RNA (siRNA) Therapeutics Market

Figure 4: Global Small Interfering RNA (siRNA) Therapeutics Market: Drivers

Figure 5: Global Small Interfering RNA (siRNA) Therapeutics Market: Challenges

Figure 6: Global Small Interfering RNA (siRNA) Therapeutics Market: Trends

Figure 7: Global Small Interfering RNA (siRNA) Therapeutics Market: Opportunity

Figure 8: Global Small Interfering RNA (siRNA) Therapeutics Market: Restraint

Figure 9: Global Small Interfering RNA (siRNA) Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Small Interfering RNA (siRNA) Therapeutics Market Value (USD Million) By Region

Figure 15: Global Small Interfering RNA (siRNA) Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Small Interfering RNA (siRNA) Therapeutics Market Value (USD Million) By Region

Figure 23: Global Small Interfering RNA (siRNA) Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Small Interfering RNA (siRNA) Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Small Interfering RNA (siRNA) Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Small Interfering RNA (siRNA) Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Small Interfering RNA (siRNA) Therapeutics Market Value (USD Million) By Region

Table 10: Global Small Interfering RNA (siRNA) Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Small Interfering RNA (siRNA) Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Small Interfering RNA (siRNA) Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Small Interfering RNA (siRNA) Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GE Basic Information And Sales Area

Table 31: GE. Products Portfolio

Table 32: Horizon Discovery Basic Information And Sales Area

Table 33: Horizon Discovery. Products Portfolio

Table 34: Thermo Scientific Basic Information And Sales Area

Table 35: Thermo Scientific. Products Portfolio

Table 36: OPKO Health Basic Information And Sales Area

Table 37: OPKO Health. Products Portfolio

Table 38: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 39: Alnylam Pharmaceuticals. Products Portfolio

Table 40: Arrowhead Research Basic Information And Sales Area

Table 41: Arrowhead Research. Products Portfolio

Table 42: Sanofi Genzyme Basic Information And Sales Area

Table 43: Sanofi Genzyme. Products Portfolio

Table 44: Genecon Biotechnologies Basic Information And Sales Area

Table 45: Genecon Biotechnologies. Products Portfolio

Table 46: Arbutus Biopharma Basic Information And Sales Area

Table 47: Arbutus Biopharma. Products Portfolio

Table 48: Silence Therapeutics Basic Information And Sales Area

Table 49: Silence Therapeutics. Products Portfolio

Table 50: Sylentis Basic Information And Sales Area

Table 51: Sylentis. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Small Interfering RNA (siRNA) Therapeutics Market Value (USD Million) By Region

Table 57: Global Small Interfering RNA (siRNA) Therapeutics Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Small Interfering RNA (siRNA) Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GE; Horizon Discovery; Thermo Scientific; OPKO Health; Alnylam Pharmaceuticals; Arrowhead Research; Sanofi Genzyme; Genecon Biotechnologies; Arbutus Biopharma; Silence Therapeutics; Sylentis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options